JUPITER NEUROSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JUPITER NEUROSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was -666.00K shares.
- JUPITER NEUROSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 675.00K shares.
- JUPITER NEUROSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 113.63K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | -666.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | |
| 2026-03-31 | 675.00K shares 10-Q · filed 2026-05-14 | |
| 2023-12-31 | 113.63K shares 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |